According to a recent LinkedIn post from Resolution Therapeutics, members of its senior clinical leadership plan to attend Digestive Disease Week in Chicago from May 2–5. The post notes that the chief medical officer, medical director, and VP of clinical operations will be on site and open to meetings on the company’s liver disease program.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights its focus on developing Regenerative Macrophage Therapy for end-stage liver disease, with lead candidate RTX001 currently in a Phase I/II trial named EMERALD. For investors, this presence at a major hepatology and gastroenterology conference may support clinical partnering, KOL engagement, and visibility for RTX001, potentially influencing future fundraising and strategic collaboration opportunities if trial data prove supportive.